Avoro Capital Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Avoro Capital Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-143,333	Closed	-$22M	–	44
2022 Q1	$22M	Buy	143,333 +24,666	+21%	+$5.07M	0.4%	32
2021 Q4	$35.1M	Buy	118,667 +12,000	+11%	+$3.52M	0.6%	25
2021 Q3	$29.6M	Hold	106,667	–	–	0.46%	30
2021 Q2	$29.2M	Buy	106,667 +234	+0.2%	+$83.8K	0.51%	32
2021 Q1	$47.4M	Buy	106,433 +3,400	+3%	+$2.42M	0.82%	25
2020 Q4	$68.7M	Buy	+103,033	New	+$60.1M	1.18%	21

Other funds holding PRAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Avoro Capital Advisors's PRAX Position: Q2 2022 in Review

Avoro Capital Advisors sold out of Praxis Precision Medicines (PRAX) in Q2 2022, closing a stake of 143,333 shares — an estimated $22M sold.

Avoro Capital Advisors first reported a position in PRAX in Q4 2020 and held it in 6 quarters. The position peaked at $68.7M in Q4 2020. 95 funds tracked by Wall St. Rank hold PRAX as of Q2 2022.

Avoro Capital Advisors reported no remaining Praxis Precision Medicines position as of Q2 2022 after selling out during the quarter.
Avoro Capital Advisors sold 143,333 Praxis Precision Medicines shares in Q2 2022, an estimated $22M.
Avoro Capital Advisors first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 6 quarters.
Avoro Capital Advisors's Praxis Precision Medicines position peaked at $68.7M in Q4 2020.
95 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2022.

Based on Avoro Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.